AbbVie Inc (ABBV)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.92% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
- AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
- Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends
- AbbVie or Altria: The One Dividend Stock I’d Hold for the Next 10 Years
- Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
- AbbVie vs. Merck: Which Pharma Stock Offers Better Value?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Optimising clinical trial design choices in inflammatory bowel disease. — BMJ Open Gastroenterol 2026 Sep 22 PMID 42772941
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther 2026 Sep 22 PMID 42771326
- Clinical and economic value of onabotulinumtoxinA vs oral pharmacotherapies in overactive bladder in the United States. — J Med Econ 2026 Dec PMID 42768867
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV. — Nat Commun 2026 Sep 1 PMID 42768041
- Next-generation tumor-agnostic targets on the horizon. — Trends Cancer 2026 Sep 21 PMID 42767904
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for AbbVie Inc.
Full ABBV Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.